About-cancer / ọgwụgwọ / adakarị-ọnwụnwa / ọrịa / gbasara ike-cancer / ọgwụgwọ
Ọgwụ Ọgwụ Ọgwụ Ọrịa Maka Ọrịa Cancer
Ọnwụnwa ụlọ ọgwụ bụ ọmụmụ nyocha metụtara mmadụ. Ọnwụnwa ahụike a dị na ndepụta a bụ maka ọgwụgwọ ọrịa kansa. Ọnwụnwa niile dị na listi ahụ na-akwado NCI.
Ihe omuma nke NCI banyere ule banyere ulo ogwu na akowa udiri udiri na uzo nke ule na otu esi aru ha. Ọnwụnwa ahụike na-eleba anya n'ụzọ ọhụrụ iji gbochie, chọpụta, ma ọ bụ gwọọ ọrịa. Ikwesiri iche echiche banyere isonye na ikpe ogwu. Gwa dọkịta gị ka o nyere gị aka ikpebi ma ọ bụrụ na ọ dị gị mma.
Ọnwụnwa 1-23 nke 23
Nivolumab mgbe ejikọtara usoro ọgwụgwọ na-agwọ ọrịa na-agwọ ndị ọrịa nwere nnukwu ihe egwu II-IIIB Cancer Cancer
Usoro nyocha nke ụlọ ọgwụ II nke a na-enweghị usoro nke ọmụmụ na-amụ ka esi eme nke ọma nivolumab mgbe usoro ọgwụgwọ agwakọtara na-arụ ọrụ n'ịgwọ ndị ọrịa nwere nnukwu ọrịa cancer II-IIIB. Immunotherapy na monoclonal na-alụso ọrịa ọgụ, dị ka nivolumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ike mkpụrụ ndụ tumo na-eto ma gbasaa.
Ọnọdụ: Ọnọdụ 744
Nivolumab nwere ma ọ bụ na-enweghị Ipilimumab na-agwọ ndị ọrịa nwere Ọrịa Canal Cancer Refractory
Usoro nyocha nke abụọ a na-amụ etu nivolumab nwere ma ọ bụ na-enweghị ipilimumab na-arụ ọrụ n'ịgwọ ndị ọrịa nwere ọrịa canal gbasara ike nke na-azabeghị ọgwụgwọ gara aga (refractory) wee gbasaa ebe ndị ọzọ na ahụ (metastatic). Immunotherapy na monoclonal antibodies, dị ka nivolumab na ipilimumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ikike nke mkpụrụ ndụ tumo na-eto ma gbasaa.
Ọnọdụ: Ọnọdụ 42
Nivolumab na Ipilimumab na-emeso ndị ọrịa nwere HIV Associated Relapsed ma ọ bụ Refractory Classical Hodgkin Lymphoma ma ọ bụ Tumor siri ike nke metastatic ma ọ bụ enweghị ike wepu ya n'ịwa ahụ
Oge nke a na-eme m nyocha ọmụmụ na ọgwụ kachasị mma nke nivolumab mgbe enyere ya na ipilimumab na ịgwọ ndị ọrịa nwere nje virus na-enweghị ike (HIV) metụtara lymphoma oge gboo nke laghachiri mgbe oge mmelite ma ọ bụ na ọ naghị anabata ọgwụgwọ, ma ọ bụ etuto siri ike nke agbasawo n'ebe ndị ọzọ n'ahụ ma ọ bụ enweghị ike wepu ya site n'ịwa ahụ. Immunotherapy na monoclonal antibodies, dị ka ipilimumab na nivolumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ikike nke mkpụrụ ndụ tumo na-eto ma gbasaa. Ipilimumab bụ ihe na-egbochi mgbochi na-eme ihe megide igwe na-akpọ cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 na-achịkwa otu akụkụ nke usoro ahụ gị ji arụ ọrụ site na imechi ya. Nivolumab bụ ụdị mgbochi nke akọwapụtara maka ọnwụ mmadụ cell (1) (PD-1), protein nke na-akpata mbibi nke mkpụrụ ndụ na-enweghịzi mgbochi. Inye ipilimumab na nivolumab nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere ọrịa lymphoma nke Hodgkin gboo ma ọ bụ etuto siri ike ma e jiri ya tụnyere ipilimumab naanị nivolumab.
Ọnọdụ: Ọnọdụ 28
Ihe omumu nke XmAb®20717 na ndi nwere isiokwu ndi ahuru elu
Nke a bụ 1 nke oge, ọtụtụ ọgwụ, ọmụmụ ihe na-arị elu na-arị elu iji kọwaa MTD / RD na usoro nke XmAb20717, iji kọwaa nchekwa na ndidi, iji nyochaa PK na immunogenicity, yana iji chọpụta ihe mgbochi nke XmAb20717 na isiokwu ndị ahọpụtara elu siri ike etuto ahụ.
Ọnọdụ: Ọnọdụ 15
Nnyocha Immuno-ọgwụ na-eme nchọpụta iji nyochaa nchekwa na arụmọrụ nke Nivolumab, na Nivolumab Combination Therapy na Nje Ọrịa Nje Virus.
Ebumnuche nke ọmụmụ a iji nyochaa nchekwa na ịdị irè nke nivolumab, na ọgwụgwọ nivolumab, iji gwọọ ndị ọrịa nwere akpụ metụtara nje. Virfọdụ nje amarawo na-ekere òkè na akpụ akpụ na uto. Ọmụmụ ihe a ga-enyocha mmetụta nke ọgwụ ndị a na-amụ, na ndị ọrịa nwere ụdị etuto ndị a: - Ọrịa Canal Canal-Agaghịzi edebanye ụdị akpụ a - Ọrịa cancer nke Cervical - Epstein Barr Virus (EBV) ezigbo ọrịa afọ - Ọ naghịzi edebanye aha a ụdị akpụ - Merkel Cell Cancer - Penile cancer - Agaghịzi edebanye ụdị akpụ a - Ọrịa cancer na nke vulvar-Agaghịzi edebanye ụdị akpụ a - Nasopharyngeal Cancer - Agaghịkwa edebanye ụdị akpụ a - Isi na Ọrịa Cancer - Agaghịkwa edebanye ụdị akpụ a
Ọnọdụ: Ọnọdụ 10
Ọmụmụ nke Pembrolizumab (MK-3475) na Ndị Soro Na-enwe Nnukwu Tumor (MK-3475-158 / KEYNOTE-158)
N'ime ọmụmụ ihe a, a ga-eji pembrolizumab sonyere ndị nwere ọtụtụ ụdị etuto siri ike dị elu (nke a na-apụghị ịkọwapụta na / ma ọ bụ nke metastatic) nke nwere ọganihu na usoro nlekọta ọgwụgwọ.
Ọnọdụ: Ọnọdụ 8
High-Dose-Rate Brachytherapy na Chemotherapy na Treatgwọ Ndị Ọrịa na Mpaghara Ntugharị ma ọ bụ Ntugharị fọdụrụnụ ma ọ bụ Ọrịa Cancer Na-aga Ọchịchị Na-abụghị Ọrụ.
Usoro nke a na-eme ka m mara ihe ọmụmụ na ọgwụ kachasị mma nke brachytherapy dị elu mgbe enyere ya na ọgwụ na-agwọ ndị ọrịa nwere ọrịa kansa ma ọ bụ gbasara ike nke laghachiri ma ọ bụ njọ ma enweghị ike ịgwọ ya. Brachytherapy, nke a makwaara dị ka ọgwụgwọ radieshon dị n'ime, na-eji ihe redioactive etinye n'ime ma ọ bụ n'akụkụ akpụ iji gbuo mkpụrụ ndụ akpụ. Ngwá ọgwụ dị elu (HDR) brachytherapy na-eji ihe ndị na-eme ihe na-eme ihe iji mezuo ọgwụ dị ukwuu na radiation n'oge dị mkpirikpi na akpụ. O nwekwara ike iziga obere radieshon na anụ ahụ dị mma dị nso ma nwee ike belata ohere nke nsonaazụ. Ọgwụ ndị a na-eji na chemotherapy, dị ka capecitabine na fluorouracil, na-arụ ọrụ n'ụzọ dị iche iche iji kwụsị uto nke mkpụrụ ndụ tumo, site na igbu mkpụrụ ndụ, site na ịkwụsị ha nkewa, ma ọ bụ site na ịkwụsị ha ịgbasa.
Ọnọdụ: Ọnọdụ 6
Pembrolizumab na-agwọ Ndị Ọrịa na Ọrịa Cancer Metastatic ma ọ bụ Obodo Ọrịa Nke Na-enweghị Ike vedwa Ahụ
Usoro ikpe nke abụọ a na-amụ etu pembrolizumab si arụ ọrụ n'ịgwọ ndị ọrịa nwere ọrịa gbasara ike nke gbasaa na ebe ndị ọzọ na ahụ ma ọ bụ nke gbasaa site na saịtị mbụ nke uto ya na anụ ahụ dị nso ma ọ bụ lymph node ma enweghị ike wepu ya n'ịwa ahụ. Immunotherapy na monoclonal antibodies, dị ka pembrolizumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ikike nke mkpụrụ ndụ tumo na-eto ma gbasaa.
Ọnọdụ: Ọnọdụ 5
Gerywa Ahụ na Treatgwọ Ndị Ọrịa na Ọdụ Anal Canal ma ọ bụ Ọrịa Perianal na nje HIV
Usoro ihe ọmụmụ nke abụọ a na-amụ ịwa ahụ n'ịgwọ ndị ọrịa nwere canal ma ọ bụ ọrịa kansa nke obere na ọ gbasaghị nke ọma na anụ ahụ na nje HIV (HIV). Surgerywa ahụ ime obodo nwere ike ịbụ ọgwụgwọ dị nchebe na mmetụta ole na ole dị obere karịa ịwa ahụ buru ibu ma ọ bụ radieshon na chemotherapy.
Ọnọdụ: Ọnọdụ 5
Nnwale iji chọpụta ma nyochaa usoro nchekwa nke ihe ọhụrụ (BI 754091) maka ndị ọrịa nwere akpụ siri ike
Ebumnuche bụ isi nke ikpe-ngbasawanye nke ikpe ahụ bụ iji chọpụta nchekwa na ndidi, yana ịchọpụta oke tozuru oke na / ma ọ bụ Ntuziaka 2 Dose (RP2D) nke BI 754091 na-adabere na ndị ọrịa nwere oke ọgwụ ọrịa na-egbu egbu (DLTs) na ndị ọrịa nwere ọrịa ọjọọ siri ike ahọrọ. A ga-enyocha nchekwa na ndidi site na nyochaa ihe omume ọjọọ (AEs), AEs dị njọ (SAE), na nrụrụ aka nyocha ụlọ nyocha, yana mgbanwe na akara ngosi dị mkpa. Ebumnuche nke abụọ bụ mkpebi nke PK profaịlụ nke BI 754091 mgbe otu na ọtụtụ doses nke BI 754091, na nyocha nke mbido nke ọrụ antitumour. N'ebe a na-agbasawanye ọgwụ nke ikpe ahụ, isi ebumnuche bụ iji nyochaa nchekwa, nrụpụta, profaịlụ PK,
Ọnọdụ: Ọnọdụ 3
Stereotactic Radiosurgery n'ịgwọ Ndị Ọrịa na Ọrịa Oligometastatic
Usoro ihe ọmụmụ nke abụọ a na-amụ otu esi arụ ọrụ redio na-arụ ọrụ n'ịgwọ ndị ọrịa nwere ọrịa kansa nke gbasaa na 5 ma ọ bụ obere akụkụ n'ime ahụ ma gụnyere akụkụ 3 ma ọ bụ obere (ọrịa oligometastatic). Stereotactic radiosurgery, nke a makwaara dị ka ọgwụgwọ radieshon nke stereotactic, bụ usoro ọgwụgwọ radieshon pụrụ iche nke na-anapụta otu nnukwu ọgwụ radieshon ozugbo na tumor ma nwee ike igbu ọtụtụ mkpụrụ ndụ tumo ma kpatara obere anụ ahụ.
Ọnọdụ: Ọnọdụ 3
Ihe omumu nke INCMGA00012 na Cancer Canam nke Anal Canal Na-esote Platinum-based Chemotherapy (POD1UM-202)
Ebumnuche nke ọmụmụ a bụ inyocha nrụpụta nke INCMGA00012 na ndị sonyere na carcinoma squamous squalous nke canal (SCAC) nwere ọganihu mgbe ịlaghachi ọgwụ na-edozi ahụ.
Ọnọdụ: Ọnọdụ 4
Artesunate na-agwọ ndị ọrịa nwere Anal Intraepithelial Neoplasia
Usoro ihe a na - eme ka m mara ihe na - emetụta mmetụta na ọgwụ kachasị mma nke artesunate na - agwọ ndị ọrịa nwere ọgwụ intraepithelial neoplasia dị elu. Anal intraepithelial neoplasia bụ mkpụrụokwu ndị nwere ike ịmalite ma ọ nwere ike ọ gaghị abụ ọrịa kansa n'ọdịnihu. Imirikiti mgbanwe ndị na-ebute ọrịa kansa bụ ihe papillomavirus (HPV) mmadụ. Artesunate nwere ike igbu mkpụrụ ndụ nwere HPV.
Ọnọdụ: Ọnọdụ 2
Ọmụmụ nke LY3434172, PD-1 na PD-L1 Bispecific Antibody, na Ọrịa Cancer
Ebumnuche bụ isi nke ọmụmụ a bụ ịtụle nchekwa na ndidi nke ọgwụ LY3434172, PD-1 / PD-L1 na-eme ihe mgbochi, na ndị sonyere na etuto ahụ siri ike.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
SL-279252 (PD1-Fc-OX40L) na Ndị nwere isiokwu Trọm siri ike ma ọ bụ Lymphomas
Nke a bụ oge 1 nke mbụ na mmadụ, akara ngosi, ọtụtụ ụlọ, mmụba ọgwụ na mmụba ọmụmụ iji chọpụta nchekwa, ndidi, PK, mgbochi akpụ ọrụ na ọgwụ pharmacodynamic nke SL-279252 na isiokwu nwere etuto siri ike ma ọ bụ lymphomas. .
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
LET-IMPT na Chekpụrụ Chemotherapy na-emeso ndị ọrịa na-achọpụta ọhụụ ọhụụ I-III Anal Canal Squamous Cell Cancer
Usoro ikpe nke II nke abụọ a na-amụ mmetụta nke LET-IMPT na chemotherapy dị mma, yana otu ha si arụ ọrụ n'ịgwọ ndị ọrịa nwere ọrịa ọhụụ I-III nke nyocha ọhụụ ọhụrụ. LET-IMPT bụ ụdị ọgwụgwọ radieshon nke na-eji proton "beamlets" dị elu iji "tee" ọgwụ radieshon ahụ n'ime ihe mgbaru ọsọ ahụ ma nwee ike inye aka igbu mkpụrụ ndụ tumo ma belata akpụ. Inye LET-IMPT na usoro ọgwụgwọ ihe eji arụ ọrụ nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere canal squamous cell cancer.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
VGX-3100 na Electroporation na Treatgwọ Ndị Ọrịa nwere Ọrịa Ọrịa HIV-Positive
Usoro nke abụọ nke oge a na-enyocha etu papillomavirus (HPV) mmadụ deoxyribonucleic acid (DNA) si agwọ ọrịa ọgwụ VGX-3100 (VGX-3100) na ọrụ electroporation na-agwọ ndị ọrịa nwere nje virus na-adịghị mma nke mmadụ (HIV). Acgba ọgwụ mgbochi sitere na DNA nwere ike inyere ahụ aka ịmalite nzaghachi dị irè iji gbuo mkpụrụ ndụ tumo. Electroporation na-enyere pores n'ime ahụ gị aka ị takeụ ọgwụ iji wusie ike sistemu gị. Inye VGX-3100 na electroporation ọnụ nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere ọnya gbasara ike dị elu.
Ọnọdụ: Ọnọdụ 2
DNA Plasmid-ngbanwe Interleukin-12 / HPV DNA Plasmids Ọgwụgwọ Ọgwụ INO-3112 na Durvalumab na-agwọ Ndị Ọrịa na Ndị Ọrịa Cancer Papatar ma ọ bụ Metastatic Associated Cancers
Usoro nyocha nke abụọ a na-amụ etu esi deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12 / human papillomavirus (HPV) DNA plasmids ọgwụ ọgwụgwọ INO-3112 na durvalumab na-arụ ọrụ n'ịgwọ ndị ọrịa nwere ọrịa papillomavirus metụtara mmadụ nke laghachiri ma ọ bụ gbasaa na ndị ọzọ ebe n'ime ahu. Ọgwụ mgbochi emere site na mkpụrụ ndụ ihe nketa nke gbanwere mkpụrụ ndụ nwere ike inyere ahụ aka ịmalite nzaghachi dị irè iji gbuo mkpụrụ ndụ tumo. Immunotherapy na monoclonal-alụso ọrịa ọgụ, dị ka durvalumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, na nwere ike igbochi ike nke mkpụrụ ndụ tumo na-eto ma na-agbasa. Inye ọgwụ plasmid -ododing interleukin-12 / HPV plasmids ọgwụgwọ ogwu INO-3112 na durvalumab nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere ọrịa papillomavirus metụtara mmadụ.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
M7824 na Ndị nwere HPV Associated Malignancies
Ndabere: Na United States, kwa afọ enwere ihe karịrị ọrịa 30,000 nke ọrịa papillomavirus (HPV) metụtara ọrịa kansa. Fọdụ n'ime ọrịa cancer ndị a anaghị enwe ọgwụgwọ ma ọ naghị eme ka usoro ọgwụgwọ dị mma karịa ya. Ndị na-eme nchọpụta chọrọ ịhụ ma ọgwụ M7824 ọhụrụ, nke na-ezube ma gbochie ụzọ nke na-egbochi usoro ahụ ji alụso ọrịa ọgụ ọgụ iji lụsoo ọrịa kansa ọgụ nwere ike ibelata etuto dị na ndị nwere ụfọdụ ọrịa cancer HPV. Ebumnuche: Iji hụ ma ọgwụ M7824 ọ na-ebute etuto ahụ. Nke ruru eru: Ndị okenye dị afọ 18 na okenye nwere ọrịa kansa metụtara ọrịa HPV. Design: A ga-enyocha ndị sonyere na akụkọ ahụike na nyocha ahụ. Ha ga-enyocha mgbaàmà ha na etu ha si arụ ọrụ ha. Ha ga enyocha ahu. Ha ga-enye ọbara na mmamịrị. Ha ga-enwe ihe nlele nke anụ ahụ ha wepụrụ ma ọ bụrụ na enweghị ya. Ndị sonyere ga-enwe electrocardiogram iji nyochaa obi ha. Mgbe ahụ ha ga - enweta ọgwụ ọgwụ site na mkpa tube dị na akwara aka. Ndị sonyere ga-enweta ọgwụ ahụ kwa izu abụọ ọ bụla maka oge 26 (afọ 1). Nke a bụ 1 N'ezie. Mgbe usoro a gasịrị, a ga-enyocha ndị sonyere mana ha agaghị ewere ọgwụ ọmụmụ ihe. Ọ bụrụ na ọnọdụ ha aka njọ, ha ga-amalite ọgwụ ọzọ. Usoro a nwere ike ịmeghachi ugboro ole ọ bụla achọrọ. Ọgwụgwọ ga-akwụsị ma ọ bụrụ na onye so ya nwere mmetụta ọjọọ ma ọ bụ ọgwụ ahụ akwụsị ịrụ ọrụ. N'ime ọmụmụ ihe ahụ dum, ndị sonyere ga-emeghachi ụfọdụ ma ọ bụ nyocha nyocha niile. Mgbe ndị sonyere kwụsịrị ị takingụ ọgwụ ahụ, ha ga-enwe nleta na-esote ma megharịa ụfọdụ nyocha nyocha. Ha ga-enweta oku ekwentị site n'oge ruo n'oge. ... Mgbe ahụ ha ga - enweta ọgwụ ọgwụ site na mkpa tube dị na akwara aka. Ndị sonyere ga-enweta ọgwụ ahụ kwa izu abụọ ọ bụla maka oge 26 (afọ 1). Nke a bụ 1 N'ezie. Mgbe usoro a gasịrị, a ga-enyocha ndị sonyere mana ha agaghị ewere ọgwụ ọmụmụ ihe. Ọ bụrụ na ọnọdụ ha aka njọ, ha ga-amalite ọgwụ ọzọ. Usoro a nwere ike ịmeghachi ugboro ole ọ bụla achọrọ. Ọgwụgwọ ga-akwụsị ma ọ bụrụ na onye so ya nwere mmetụta ọjọọ ma ọ bụ ọgwụ ahụ akwụsị ịrụ ọrụ. N'ime ọmụmụ ihe ahụ dum, ndị sonyere ga-emeghachi ụfọdụ ma ọ bụ nyocha nyocha niile. Mgbe ndị sonyere kwụsịrị ị takingụ ọgwụ ahụ, ha ga-enwe nleta na-esote ma megharịa ụfọdụ nyocha nyocha. Ha ga-enweta oku ekwentị site n'oge ruo n'oge. ... Mgbe ahụ ha ga - enweta ọgwụ ọgwụ site na mkpa tube dị na akwara aka. Ndị sonyere ga-enweta ọgwụ ahụ kwa izu abụọ ọ bụla maka oge 26 (afọ 1). Nke a bụ 1 N'ezie. Mgbe usoro a gasịrị, a ga-enyocha ndị sonyere mana ha agaghị ewere ọgwụ ọmụmụ ihe. Ọ bụrụ na ọnọdụ ha aka njọ, ha ga-amalite ọgwụ ọzọ. Usoro a nwere ike ịmeghachi ugboro ole ọ bụla achọrọ. Ọgwụgwọ ga-akwụsị ma ọ bụrụ na onye so ya nwere mmetụta ọjọọ ma ọ bụ ọgwụ ahụ akwụsị ịrụ ọrụ. N'ime ọmụmụ ihe ahụ dum, ndị sonyere ga-emegharị ụfọdụ ma ọ bụ nyocha nyocha niile. Mgbe ndị sonyere kwụsịrị ị takingụ ọgwụ ahụ, ha ga-enwe nleta na-esote ma megharịa ụfọdụ nyocha nyocha. Ha ga-enweta oku ekwentị site n'oge ruo n'oge. ... a ga-enyocha ndị sonyere mana ha agaghị ewere ọgwụ ọmụmụ ihe. Ọ bụrụ na ọnọdụ ha aka njọ, ha ga-amalite ọgwụ ọzọ. Usoro a nwere ike ịmeghachi ugboro ole ọ bụla achọrọ. Ọgwụgwọ ga-akwụsị ma ọ bụrụ na onye so ya nwere mmetụta ọjọọ ma ọ bụ ọgwụ ahụ akwụsị ịrụ ọrụ. N'ime ọmụmụ ihe ahụ dum, ndị sonyere ga-emeghachi ụfọdụ ma ọ bụ nyocha nyocha niile. Mgbe ndị sonyere kwụsịrị ị takingụ ọgwụ ahụ, ha ga-enwe nleta na-esote ma megharịa ụfọdụ nyocha nyocha. Ha ga-enweta oku ekwentị site n'oge ruo n'oge. ... a ga-enyocha ndị sonyere mana ha agaghị ewere ọgwụ ọmụmụ ihe. Ọ bụrụ na ọnọdụ ha aka njọ, ha ga-amalite ọgwụ ọzọ. Usoro a nwere ike ịmeghachi ugboro ole ọ bụla achọrọ. Ọgwụgwọ ga-akwụsị ma ọ bụrụ na onye so ya nwere mmetụta ọjọọ ma ọ bụ ọgwụ ahụ akwụsị ịrụ ọrụ. N'ime ọmụmụ ihe ahụ dum, ndị sonyere ga-emeghachi ụfọdụ ma ọ bụ nyocha nyocha niile. Mgbe ndị sonyere kwụsịrị ị takingụ ọgwụ ahụ, ha ga-enwe nleta na-esote ma megharịa ụfọdụ nyocha nyocha. Ha ga-enweta oku ekwentị site n'oge ruo n'oge. ... Mgbe ndị sonyere kwụsịrị ị takingụ ọgwụ ahụ, ha ga-enwe nleta na-esote ma megharịa ụfọdụ nyocha nyocha. Ha ga-enweta oku ekwentị site n'oge ruo n'oge. ... Mgbe ndị sonyere kwụsịrị ị takingụ ọgwụ ahụ, ha ga-enwe nleta na-esote ma megharịa ụfọdụ nyocha nyocha. Ha ga-enweta oku ekwentị site n'oge ruo n'oge. ...
Ọnọdụ: Instlọ Ọrụ Ahụike nke Ahụike Mba, Bethesda, Maryland
MnSOD Mimetic BMX-001 na-agwọ ndị ọrịa nwere Ọrịa Canal Na-aga Ọgwụ Mgbasa Ọgwụ na Chemotherapy
Oge nke a na-anwale ihe ọmụmụ MnSOD kachasị mma BMX-001 iji belata mmetụta ndị ọrịa na-arịa ọrịa gbasara ike na-agwọ ọrịa radieshon na chemotherapy. Ngwurugwu Chemoprotective, dị ka BMX-001, nwere ike ichebe mkpụrụ ndụ nkịtị site na nsonaazụ nke chemotherapy mgbe ọ na-eme ka igbu egbu egbu.
Ọnọdụ: Mahadum nke Nebraska Medical Center, Omaha, Nebraska
Atezolizumab na Bevacizumab na-emeso ndị ọrịa na-arịa ụfụ siri ike
Usoro nyocha nke abụọ a na-amụ etu ọrụ atezolizumab na bevacizumab si arụ ọrụ n'ịgwọ ndị ọrịa nwere akpụ siri ike. Immunotherapy na monoclonal-alụso ọrịa ọgụ, dị ka atezolizumab na bevacizumab, nwere ike inyere ahụ ji alụso ọrịa ọgụ usoro cancer, na nwere ike igbochi ikike nke akpụ mkpụrụ ndụ na-eto ma na-agbasa.
Ọnọdụ: MD Anderson Cancer Center, Houston, Texas
Ọgwụ Mgbochi na Cyclophosphamide na-agwọ ndị ọrịa na HLA-A * 02 Positive Relapsed, Refractory, ma ọ bụ Metastatic HPV16 metụtara Oropharyngeal, Cervical, or Anal Cancer
Usoro a nke Ib / II na-amụ banyere mmetụta na ọgwụ kachasị mma nke HPV16-E711-19 nanomer ogwu DPX-E7 na iji hụ otú o si arụ ọrụ mgbe e nyere ya na cyclophosphamide n'ịgwọ ndị ọrịa HLA-A * 02 dị mma, papillomavirus mmadụ 16 ( HPV16) metụtara oropharyngeal, cervical, ma ọ bụ gbasara ike kansa nke laghachiri, anaghị anabata ọgwụgwọ, ma ọ bụ gbasaa n'akụkụ ndị ọzọ nke ahụ. Ọgwụ mgbochi emere site na mkpụrụ ndụ ihe nketa nke gbanwere mkpụrụ ndụ nwere ike inyere ahụ aka ịmalite nzaghachi dị irè iji gbuo mkpụrụ ndụ tumo. Ọgwụ a na-eji na chemotherapy, dị ka cyclophosphamide, na-arụ ọrụ n'ụzọ dị iche iche iji kwụsị uto nke mkpụrụ ndụ etuto, site na igbu mkpụrụ ndụ, site na ịkwụsị ha nkewa, ma ọ bụ site na ịkwụsị ha ịgbasa. Inye HPV16-E711-19 nanomer ogwu DPX-E7 tinyere cyclophosphamide nwere ike ịrụ ọrụ nke ọma n'ịgwọ ndị ọrịa nwere oropharyngeal metụtara HPV16,
Ọnọdụ: Dana-Farber Cancer Institute, Boston, Massachusetts
Nivolumab na Ipilimumab na-agwọ Ndị Ọrịa nwere Tumo
Usoro ihe ọmụmụ II nke abụọ a bụ nivolumab na ipilimumab n'ịgwọ ndị ọrịa nwere akpụ etuto. Immunotherapy na monoclonal antibodies, dị ka nivolumab na ipilimumab, nwere ike inyere usoro ahụ ji alụso ọrịa ọgụ ọgụ megide kansa, ma nwee ike igbochi ikike nke mkpụrụ ndụ tumo na-eto ma gbasaa. Ọnwụnwa a na-edebanye aha ndị otu maka ngalaba ndị a na-adabere na ọnọdụ: 1. Epithelial etuto ahụ nke oghere imi, sinuses, nasopharynx: A) Ngwakọta carcinoma squamous nwere ọdịiche nke oghere imi, sinuses, na nasopharynx na trachea (ewepu laryngeal, nasopharyngeal cancer [NPC] , na carcinoma squamous cell nke isi na olu [SCCHN]) B) Adenocarcinoma na ụdị dị iche iche nke oghere imi, sinuses, na nasopharynx (emechibidoro 07/27/2018) / 20/2018) 3. Salivary gland ụdị etuto ahụ nke isi na n'olu, egbugbere ọnụ, esophagus, afo, trachea na ngụgụ, ara na ebe ọzọ (emechi ka mpụta) 4. Carcinoma na-adịghị iche nke eriri afọ (GI) 5. Adenocarcinoma nwere ụdị dị iche iche nke eriri afọ (emechi emechi) 05/10/2018) 6. Squinous cell carcinoma nke nwere ọtụtụ traktị GI (afọ obere eriri afọ, colon, rectum, pancreas) (emechibidoro na 10/17/2018) 7. Fibromixoma na adenocarcinoma dị ala (pseudomixoma peritonei) nke ihe mgbakwunye na ovary (emechi iji nweta 03/20/2018) 8. Ọrịa na-adịghị ahụkebe pancreatic gụnyere acinar cell carcinoma, cystadenocarcinoma mucinous ma ọ bụ serous cystadenocarcinoma. Pancreatic adenocarcinoma erughị eru 9. Intrahepatic cholangiocarcinoma (emechibidoro iji nweta 03/20/2018) 10. Extrahepatic cholangiocarcinoma na bile duct etuto (mechiri emechi iji 03/20/2018) 11. Sarcomatoid carcinoma nke ngụgụ 12. Bronchoalveolar carcinoma lung. A na-akpọkwa ọnọdụ a adenocarcinoma dị na mbelata, adenocarcinoma pere mpe, adenocarcinoma pere mpe, ma ọ bụ adenocarcinoma na-abaghị uru 13. Ọrịa na-abụghị epithelial nke ovary: A) Akwara nke Germ nke ovary B) accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (emechibidoro 04/15/2019) 15. Carcinoma nke na-agbanwe agbanwe na-abụghị nke akụrụ, pelvis, ureter, ma ọ bụ eriri afo (emechi iji mụta 04 / 15/2019) 16. Ọkpụkpụ mkpụrụ nke mkpụrụ ndụ na etuto ahụ izizi: Apocrine tumors / extramammary Paget's ọrịa 40. Peritoneal mesothelioma 41. Basal cell carcinoma 42. Clear cell cervical cancer 43. Esthenioneuroblastoma 44. Ecinetrial carcinosarcoma (ajọ ọgwa agwakọta Mullerian etuto) (emechibidoro iji ọnụ) 45. cell cell cervical endometrial 46. Clear cell cancer cancer nke ovarian 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Obere cell carcinoma nke ovary, ụdị hypercalcemic 50. PD-L1 kwupụtara etuto 51. Angiosarcoma 52. Ọkwa neuroendocrine carcinoma dị elu (ụbụrụ neuroendocrine tumor [PNET] kwesịrị debanye aha na Cohort 22; a na-edebanye aha carcinomas na-egbu egbu na-abanye na Cohort 53). Obere akwara akwara adighi eru 53. Ọgwụgwọ-onye na - apụta obere obere neuroendocrine prostate cancer (t-SCNC) Clear cell cervical cancer 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (ajọ ọgwa agwakọta Mullerian etuto) (emechi iji nweta) 45. Clear cell cervical endometrial cancer 46. Clear cell ovarian cancer 47. Gestational trophoblastic ọrịa (GTD) 48. Gallbladder cancer 49. Obere cell carcinoma nke ovary, ụdị hypercalcemic nke 50. PD-L1 na-ebuwanye ibu etuto 51. Angiosarcoma 52. Ọkpụkpụ neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] kwesịrị ịdebanye aha na Cohort 22; prostatic neuroendocrine carcinomas kwesịrị ịbanye na Cohort 53). Obere akwara akwara adighi eru 53. Ọgwụgwọ-onye na - apụta obere obere neuroendocrine prostate cancer (t-SCNC) Clear cell cervical cancer 43. Esthenioneuroblastoma 44. Endometrial carcinosarcoma (ajọ ọgwa agwakọta Mullerian etuto) (emechi iji nweta) 45. Clear cell cervical endometrial cancer 46. Clear cell ovarian cancer 47. Gestational trophoblastic ọrịa (GTD) 48. Gallbladder cancer 49. Obere cell carcinoma nke ovary, ụdị hypercalcemic nke 50. PD-L1 na-ebuwanye ibu etuto 51. Angiosarcoma 52. Ọkpụkpụ neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] kwesịrị ịdebanye aha na Cohort 22; prostatic neuroendocrine carcinomas kwesịrị ịbanye na Cohort 53). Obere akwara akwara adighi eru 53. Ọgwụgwọ-onye na - apụta obere obere neuroendocrine prostate cancer (t-SCNC) Clear cell ovarian cancer 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Obere carcinoma nke ovary, ụdị hypercalcemic 50. PD-L1 tumoro tumor 51. Angiosarcoma 52. Ọkwa dị elu neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET) ] kwesiri ịdebanye aha na Cohort 22; prostate neuroendocrine carcinomas kwesịrị ịbanye na Cohort 53). Obere akwara akwara adighi eru 53. Ọgwụgwọ-onye na - apụta obere obere neuroendocrine prostate cancer (t-SCNC) Clear cell ovarian cancer 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Obere carcinoma nke ovary, ụdị hypercalcemic 50. PD-L1 tumoro tumor 51. Angiosarcoma 52. Ọkwa dị elu neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET) ] kwesịrị ịdebanye aha na Cohort 22; prostate neuroendocrine carcinomas kwesịrị ịbanye na Cohort 53). Obere akwara akwara adighi eru 53. Ọgwụgwọ-onye na - apụta obere obere neuroendocrine prostate cancer (t-SCNC) prostate neuroendocrine carcinomas kwesịrị ịbanye na Cohort 53). Obere akwara akwara adighi eru 53. Ọgwụgwọ-onye na - apụta obere obere neuroendocrine prostate cancer (t-SCNC) prostate neuroendocrine carcinomas kwesịrị ịbanye na Cohort 53). Obere akwara akwara adighi eru 53. Ọgwụgwọ-onye na - apụta obere obere neuroendocrine prostate cancer (t-SCNC)
Ọnọdụ: Ọnọdụ 878
